Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus docetaxel rechallenge in metastatic castration-resistant prostate cancer previously treated with docetaxel at initiation of hormone therapy
ISRCTN16465571Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Cabazitaxel plus prednisolone with Docetaxel rechallenge plus prednisolone (2 arms). Primary endpoint: Clinical progression-free survival. Started Mar 2013; status: completed.
02
Drugs
cabazitaxeldocetaxelprednisolone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ISRCTN16465571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16465571.